Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Regeneron Pharma Drug Patent Portfolio

Regeneron Pharma owns 1 purple book drug protected by 72 US patents Given below is the list of Regeneron Pharma's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11525833 Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis 29 Nov, 2040
Active
US11053280 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
Active
US11104715 Methods for producing aflibercept in chemically defined media having reduced aflibercept variants 18 Aug, 2040
Active
US11174283 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
Active
US11186625 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
Active
US11299532 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
Active
US11306135 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
Active
US11459373 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
Active
US11459374 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
Active
US11472861 Methods for producing aflibercept in chemically defined media having reduced aflibercept variants 18 Aug, 2040
Active
US11485770 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
Active
US11505593 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
Active
US11535663 Methods for producing aflibercept in chemically defined media having reduced aflibercept variants 18 Aug, 2040
Active
US11542317 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
Active
US11548932 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
Active
US11732025 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
Active
US11753459 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
Active
US11793926 Medical device packaging and related methods 29 Jul, 2040
Active
US11478588 Needle shield grip devices and related methods 25 Jul, 2040
Active
US11439758 Devices and methods for precision dose delivery 04 Jun, 2040
Active
US11555176 Cell culture medium for eukaryotic cells 27 Jan, 2040
Active
US11850407 Needle shield grip devices and related methods 18 Sep, 2039
Active
US11160918 Medical device packaging and related methods 29 Jul, 2039
Active
US10973879 Use of a VEGF antagonist to treat angiogenic eye disorders 17 May, 2039
Active
US11103552 High concentration VEGF receptor fusion protein containing formulations 15 May, 2039
Active
US11433186 Devices and methods for precision dose delivery 12 Dec, 2038
Active
US11769597 Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF 04 Dec, 2038
Active
US11788102 CHO integration sites and uses thereof 13 Sep, 2038
Active
US10905786 Sterilisation method 06 Mar, 2038
Active
US10918754 Sterilisation method 06 Mar, 2038
Active
US11680930 Methods and systems for chromatography data analysis 25 Oct, 2037
Active
US11577025 Devices and methods for overfilling drug containers 06 Oct, 2037
Active
USD961376 Packaging 23 Aug, 2037
Active
USD961377 Packaging 23 Aug, 2037
Active
US10182969 Aseptic piercing system and method 13 Jul, 2037
Active
US11918785 Devices and methods for overfilling drug containers 29 Jun, 2037
Active
US10669594 Compositions and methods for detecting a biological contaminant 12 Feb, 2037
Active
US11549154 Compositions and methods for detecting a biological contaminant 25 Dec, 2036
Active
USD934069 Packaging 26 Oct, 2036
Active
US10927342 Taurine supplemented cell culture medium and methods of use 03 Aug, 2036
Active
US11312936 Taurine supplemented cell culture medium and methods of use 03 Aug, 2036
Active
USD906102 Packaging 29 Dec, 2035
Active
US11268109 CHO integration sites and uses thereof 21 Oct, 2035
Active
US9816110 CHO integration sites and uses thereof 21 Oct, 2035
Active
US9315281 System and methods for use in dispensing biopharmaceutical materials 16 Sep, 2034
Active
USD858754 Syringe cap 03 Sep, 2034
Active
US11332771 Serum-free cell culture medium 14 Mar, 2034
Active
US11970724 Serum-free cell culture medium 14 Mar, 2034
Active
US11707506 Use of a VEGF antagonist to treat angiogenic eye disorders 03 Jun, 2032
Active
US9254338 Use of a VEGF antagonist to treat angiogenic eye disorders 22 May, 2032
Active
US10130681 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
Active
US10828345 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
Active
US10857205 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
Active
US10888601 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
Active
US11253572 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
Active
US11559564 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
Active
US11975045 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
Active
US11986511 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
Active
US9669069 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
Active
US7771997 Enhanced expression and stability regions 02 Jul, 2028
Active
US10415055 Enhanced expression and stability regions 04 Jun, 2028
Active
US9222106 Enhanced expression and stability regions 04 Jun, 2028
Active
US9562238 Enhanced expression and stability regions 04 Jun, 2028
Active
US9932605 Enhanced expression and stability regions 04 Jun, 2028
Active
US10464992 VEGF antagonist formulations suitable for intravitreal administration 14 Jun, 2027
Active
US11066458 VEGF antagonist formulations suitable for intravitreal administration 14 Jun, 2027
Active
US11084865 VEGF antagonist formulations suitable for intravitreal administration 14 Jun, 2027
Active
US11732024 VEGF antagonist formulations suitable for intravitreal administration 14 Jun, 2027
Active
US10406226 Method of manufacturing VEGF antagonist fusion proteins 22 Mar, 2026
Active
USD1035436 Packaging 16 Jul, 2024
Active
US7070959 Modified chimeric polypeptides with improved pharmacokinetic properties 16 Jun, 2023
Active
US10857231 Formulations of VEG antagonist fusion proteins and method of manufacturing them NA
Active


Regeneron Pharma's Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Regeneron Pharma:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma Regeneron Pharmaceuticals NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma Regeneron Pharmaceuticals NA RECRUITING
(Sep 1, 2026)
PHASE3
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation Regeneron Pharmaceuticals NA RECRUITING
(Sep 1, 2026)
PHASE2
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) Regeneron Pharmaceuticals NA RECRUITING
(Sep 1, 2026)
PHASE3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation Regeneron Pharmaceuticals NA RECRUITING
(Sep 1, 2026)
PHASE3
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma Regeneron Pharmaceuticals NA RECRUITING
(Aug 1, 2026)
PHASE3
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation Regeneron Pharmaceuticals NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease Regeneron Pharmaceuticals NA RECRUITING
(Aug 1, 2026)
PHASE3
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers Regeneron Pharmaceuticals NA RECRUITING
(Aug 1, 2026)
PHASE3
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD Regeneron Pharmaceuticals NA RECRUITING
(Aug 1, 2026)
PHASE2
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer Regeneron Pharmaceuticals NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments Regeneron Pharmaceuticals NA RECRUITING
(Jun 1, 2026)
PHASE1
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery Regeneron Pharmaceuticals NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) Regeneron Pharmaceuticals NA WITHDRAWN
(Jun 1, 2026)
PHASE2, PHASE3
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Regeneron Pharmaceuticals NA COMPLETED
(May 1, 2026)
PHASE3
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid Regeneron Pharmaceuticals NA COMPLETED
(May 1, 2026)
PHASE2, PHASE3
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer Regeneron Pharmaceuticals NA TERMINATED
(May 1, 2026)
PHASE2
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Regeneron Pharmaceuticals NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3


Regeneron Pharma Drug List

Given below is the complete list of Regeneron Pharma's drugs and the patents protecting them.


1. Eylea

Eylea is protected by 72 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11525833 Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis 29 Nov, 2040
(14 years from now)
Active
US11053280 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
(13 years from now)
Active
US11104715 Methods for producing aflibercept in chemically defined media having reduced aflibercept variants 18 Aug, 2040
(13 years from now)
Active
US11174283 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
(13 years from now)
Active
US11186625 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
(13 years from now)
Active
US11299532 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
(13 years from now)
Active
US11306135 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
(13 years from now)
Active
US11459373 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
(13 years from now)
Active
US11459374 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
(13 years from now)
Active
US11472861 Methods for producing aflibercept in chemically defined media having reduced aflibercept variants 18 Aug, 2040
(13 years from now)
Active
US11485770 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
(13 years from now)
Active
US11505593 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
(13 years from now)
Active
US11535663 Methods for producing aflibercept in chemically defined media having reduced aflibercept variants 18 Aug, 2040
(13 years from now)
Active
US11542317 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
(13 years from now)
Active
US11548932 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
(13 years from now)
Active
US11732025 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
(13 years from now)
Active
US11753459 Anti-VEGF protein compositions and methods for producing the same 18 Aug, 2040
(13 years from now)
Active
US11793926 Medical device packaging and related methods 29 Jul, 2040
(13 years from now)
Active
US11478588 Needle shield grip devices and related methods 25 Jul, 2040
(13 years from now)
Active
US11439758 Devices and methods for precision dose delivery 04 Jun, 2040
(13 years from now)
Active
US11555176 Cell culture medium for eukaryotic cells 27 Jan, 2040
(13 years from now)
Active
US11850407 Needle shield grip devices and related methods 18 Sep, 2039
(12 years from now)
Active
US11160918 Medical device packaging and related methods 29 Jul, 2039
(12 years from now)
Active
US10973879 Use of a VEGF antagonist to treat angiogenic eye disorders 17 May, 2039
(12 years from now)
Active
US11103552 High concentration VEGF receptor fusion protein containing formulations 15 May, 2039
(12 years from now)
Active
US11433186 Devices and methods for precision dose delivery 12 Dec, 2038
(12 years from now)
Active
US11769597 Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF 04 Dec, 2038
(12 years from now)
Active
US11788102 CHO integration sites and uses thereof 13 Sep, 2038
(11 years from now)
Active
US10905786 Sterilisation method 06 Mar, 2038
(11 years from now)
Active
US10918754 Sterilisation method 06 Mar, 2038
(11 years from now)
Active
US11680930 Methods and systems for chromatography data analysis 25 Oct, 2037
(11 years from now)
Active
US11577025 Devices and methods for overfilling drug containers 06 Oct, 2037
(11 years from now)
Active
USD961376 Packaging 23 Aug, 2037
(10 years from now)
Active
USD961377 Packaging 23 Aug, 2037
(10 years from now)
Active
US10182969 Aseptic piercing system and method 13 Jul, 2037
(10 years from now)
Active
US11918785 Devices and methods for overfilling drug containers 29 Jun, 2037
(10 years from now)
Active
US10669594 Compositions and methods for detecting a biological contaminant 12 Feb, 2037
(10 years from now)
Active
US11549154 Compositions and methods for detecting a biological contaminant 25 Dec, 2036
(10 years from now)
Active
USD934069 Packaging 26 Oct, 2036
(10 years from now)
Active
US10927342 Taurine supplemented cell culture medium and methods of use 03 Aug, 2036
(9 years from now)
Active
US11312936 Taurine supplemented cell culture medium and methods of use 03 Aug, 2036
(9 years from now)
Active
USD906102 Packaging 29 Dec, 2035
(9 years from now)
Active
US11268109 CHO integration sites and uses thereof 21 Oct, 2035
(9 years from now)
Active
US9816110 CHO integration sites and uses thereof 21 Oct, 2035
(9 years from now)
Active
US9315281 System and methods for use in dispensing biopharmaceutical materials 16 Sep, 2034
(7 years from now)
Active
USD858754 Syringe cap 03 Sep, 2034
(7 years from now)
Active
US11332771 Serum-free cell culture medium 14 Mar, 2034
(7 years from now)
Active
US11970724 Serum-free cell culture medium 14 Mar, 2034
(7 years from now)
Active
US11707506 Use of a VEGF antagonist to treat angiogenic eye disorders 03 Jun, 2032
(5 years from now)
Active
US9254338 Use of a VEGF antagonist to treat angiogenic eye disorders 22 May, 2032
(5 years from now)
Active
US10130681 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
(5 years from now)
Active
US10828345 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
(5 years from now)
Active
US10857205 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
(5 years from now)
Active
US10857205 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
(5 years from now)
Active
US10888601 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
(5 years from now)
Active
US11253572 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
(5 years from now)
Active
US11559564 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
(5 years from now)
Active
US11975045 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
(5 years from now)
Active
US11986511 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
(5 years from now)
Active
US9669069 Use of a VEGF antagonist to treat angiogenic eye disorders 11 Jan, 2032
(5 years from now)
Active
US7771997 Enhanced expression and stability regions 02 Jul, 2028
(1 year, 8 months from now)
Active
US10415055 Enhanced expression and stability regions 04 Jun, 2028
(1 year, 7 months from now)
Active
US9222106 Enhanced expression and stability regions 04 Jun, 2028
(1 year, 7 months from now)
Active
US9562238 Enhanced expression and stability regions 04 Jun, 2028
(1 year, 7 months from now)
Active
US9932605 Enhanced expression and stability regions 04 Jun, 2028
(1 year, 7 months from now)
Active
US10464992 VEGF antagonist formulations suitable for intravitreal administration 14 Jun, 2027
(8 months from now)
Active
US11066458 VEGF antagonist formulations suitable for intravitreal administration 14 Jun, 2027
(8 months from now)
Active
US11084865 VEGF antagonist formulations suitable for intravitreal administration 14 Jun, 2027
(8 months from now)
Active
US11732024 VEGF antagonist formulations suitable for intravitreal administration 14 Jun, 2027
(8 months from now)
Active
US10406226 Method of manufacturing VEGF antagonist fusion proteins 22 Mar, 2026
(6 months ago)
Expired
USD1035436 Packaging 16 Jul, 2024
(2 years ago)
Expired
US7070959 Modified chimeric polypeptides with improved pharmacokinetic properties 16 Jun, 2023
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eylea's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List